Figure 4 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma

<p>Romidepsin has the largest overall therapeutic index of all 13 hits from the initial screen. Data represent dose–response experiments for top 13 hits from initial screen. Ratios of TD<sub>50</sub>/sarcosphere (Sarco) ED<sub>50</sub> reflect therapeutic indices with NHOst and non-transformed human SAEC. White on the color scale is set at the median of the overall row means, shown in the first column. TD<sub>50</sub>s, doses that reduce metabolic activity of NHOst and SAEC by 50%, are shown in Supplementary Figs. S5A and S6A. The TD<sub>50</sub>/ED<sub>50</sub> ratios are shown in Supplementary Figs. S5B–S5D and S6B–S6D. TD<sub>50</sub>s were determined in <i>N</i> = 3 independent dose–response experiments with each drug. Each experiment included at least three culture wells per group. ED<sub>50</sub>s, doses that reduce metabolic activity of 143B, LM7, or MG63.3-GFP sarcospheres by 50%, are shown in Supplementary Fig. S1B–S1D and Supplementary Table S3.</p>